# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.






図 1




				÷
				•
			·	


図2



			•



1



WO 01/04301

4/10

図 4





## G3PDH














凶 6			550
PSEC67:	501	ACAGGGCTGCACGCCCTTC-CTACGTGCGCTAGGCTGGGGACTGGGGACCCGACGGCG-G	558
	00	AC G GC GCA GCGC TT CTACG G G AGGCTG G C G GA C CGG G ACCGCGCGCGCGCGCGCGCGC	151
m. FATP3:			
PSEC67:	550	CGACAGCGGCGAGGGGAGCGCTGGAGAAGGCGAGCGGGCAGCGCCGG-GGAGCCGG-AGAT	616
raccor.		TO THE BUSINESS GRAPH AS A CAPACITY OF THE PROPERTY OF THE PRO	
m. FATP3:	152	CT-C-GCGCCTTTCTGCGCGCACGGGGCTG-GACCGGGGGCCGCCGAGGCTCGGGCAGGG	208
		T1/4/4/2019191919191919191919191919191919191919	670
PSEC67:	617	GCAGCGCC-GGAAG-CGG-CGCG-GAGTTTGCCGGAGGG-GACGGTGCCGCCAGAGGT GCAGC GGAAG CG CGCG G G T CCGG GG GA G GC GC AGAGG	010
2.500	000	GCAGC GGAAG CG CGCG G T CCGG GG G	266
m. FATP3:			
PSEC67:	671	GGAGGAGCCGCCCCCTCTGTCACCTGGAGCAACTGTGGCGCTGCTCCTCCCCCGCTGGC	730
JECUT.		CA CA CCCC CCCCTCTC CACC GG GC AC GTGGCGCTGCTCCTCCC GC GGC	
m. FATP3:	267	-GACGA-CCGCGCCCCCTCTGGCACCCGGGGCGACCGTGGCGCTGCTCCTCCCAGCGGGC	324
		TOTAL TATAL AND A CONTROL OF THE CON	790
PSEC67:	731	CCAGAGTTTCTGTGGCTCTGGTTCGGGCTGGCCAAGGCCGGCC	150
EATTO .	205	CCGGATTCCTTTGGATTTGGTTCGGACTGGCCAAAGCTGGCCTGCGCACGGCCTTTGTG	384
m. FATP3:			
PSEC67:	791	CCCACCGCCTGCGCCGGGCCCCCTGCTGCACTGCCTCCGCAGCTGCGGCGCGCGC	850
I SECOT .		CONTROL T COOR OF CONTROL CONTROL CONTROL OF THE CO	
m. FATP3:	385	CCCACCGCTTTACGCCGAGGACCCCTGCTGCACTGCCTCCGCAGCTGCGGTGCGAGTGCG	444
1		CTGGTGCTGGCGCCAGAGTTTCTGGAGTCCCTGGAGCCGGACCTGCCCGCCC	910
PSEC67:	851	CTGGTGCTGGC CAGAGTT CTGGAGTCCCTGGAGCCGGACCTGCC GCC TGAGAGCCCTGC GCC TGAGAGCCCTGCC GCC TGAGAGCCCGACCTGCC GCC TGAGAGCCCGACCTGCC GCC TGAGAGCCCGACCTGCC GCC TGAGAGCCCCGACCTGCC GCC TGAGAGCCCCGACCTGCC GCC TGAGAGCCCCGACCTGCC GCC TGAGAGCCCCTGCC GCC TGAGAGCCCTGCC GCC TGACACCTGCC GCC TGACACCTACACACACACACACACACACACACACACACAC	310
- EATD2.	AAE	CTCGTGCTGGCCACAGAGTTCCTGGAGTCCCTGGAGCCGGACCTGCCGGCCTTGAGAGCC	504
m. PAIPS.			
PSEC67:	911	ATGGGGCTCCACCTGTGGGCTGCAGGCCCAGGAACCCACCC	970
		ATCCCCTCCACCT TCCCC C CCCCC G AAC A GCTGGAAL AGG ALLIG	
m. FATP3:	505	ATGGGGCTCCACCTATGGGCGACGGGCCCTGAAACTAATGTAGCTGGAATCAGCAATTTG	<b>504</b>
		CTGGCTGAAGTGTCCGCTGAAGTGGATGGGCCAGTGCCAGGATACCTCTCTTCCCCCCAG	1030
PSEC67:	971	CT C GAAG C G AAGTGGATG GCCAGTGCC GG TACCTCTCT CCCCCCAG	;
m EATD2	565	CTATCGGAAGCAGCAGACCAAGTGGATGAGCCAGTGCCGGGGTACCTCTCTGCCCCCCAG	624
3			
PSEC67:	1031	AGCATAACAGACACGTGCCTGTACATCTTCACCTCTGGCACCACGGGCCTCCCCAAGGCT	1090
1		A CATAA CACAC TCCCTCTACATCTTCACTTTTACTTTTACTACAC AC CACCE CUCHAUGUI	
m. FATP3	625	A CATAA GACAC TGCCTGTACATCTTCACCTCTGGCACTACTGGCCTGCCCAAGGCT	U0 <del>1</del>
Danage		GCTCGGATCAGTCATCTGAAGATCCTGCAATGCCAGGGCTTCTATCAGCTGTGTGGTGTC	1150
1		COTOC ATCACTCATCTCAAC T CT CA TGCCAGGG TTCTA CA CIGIGIGG GIU	,
m EATDS	. 681	GCTCGAATCAGTCATCTGAAGGTTCTACAGTGCCAGGGATTCTACCATCTGTGTGGAGTC	744
1			
PSEC67:	1151	CACCAGGAAGATGTGATCTACCTCGCCCTCCCACTCTACCACATGTCCGGTTCCCTGCTC	1210
1		CACCACCA CA CTCATCTACCTCCC CTCCCACT TACCCACATGLE GG 10001 UI	J
m. FATP3	: 74	CACCAGGAGGACGTGATCTACCTCGCACTCCCACTGTACCACATGTCTGGCTCCCTTCTC	J 0U4
DODGGG	101	1 GGCATCGTGGGCTGCATGGGCCATTGGGGCCACAGTGGTGCTGAAATCCAAGTTCTCGGC	Г 1270
a l		COCAT CTCCCCTCC TCCCCATTCCCCCCAC GTGGTGCTGAAA CCAAGIICIC GC	1
T EATD?	• <u>ഉ</u> വ	5 GCATTGTGGGCTGCTTGGGCATTGGGGCCACCGTGGTGCTGAAACCCAAGTTCTCAGC	Г 864
Im r. Urr o	. 00	0 000/11/01/000/10/11/01/01/01	

	i	
		•
		•

図 7	
ľ	GGTCAGTTCTGGGAAGATTGCCAGCAGCACAGGGTGACGGTGTTCCAGTACATTGGGGAG 1330 G CAGTTCTGGGA GATTGCCAG A CACAGGGTGAC GTGTTCCAGTACATTGGGGAG
i .	AGCCAGTTCTGGGACGATTGCCAGAAACACAGGGTGACAGTGTTCCAGTACATTGGGGAG 924
•	CTGTGCCGATACCTTGTCAACCAGCCCCCGAGCAAGGCAGAACGTGGCCATAAGGTCCGG 1390 TGTGCCGATACCT GTCAACCAGCCCCCGAGCAAGGCAGA TG CCATAAGGT CG
	TTGTGCCGATACCTCGTCAACCAGCCCCCGAGCAAGGCAGAGTTTGACCATAAGGTGCGC 984
i	CTGGCAGTGGGCAGCGGCTGCGCCCAGATACCTGGGAGCGTTTTGTGCGGCGCTTCGGG 1450 TGGCAGTGGGCAG GGG TGCGCCCAGA ACCTGGGAGCGTTT TGCGGGCG TT GG
1	5 TTGGCAGTGGGCAGTGCGCTTGCGCCCAGACACCTGGGAGCGTTTCCTGCGGCGATTTGGA 1044
1	1 CCCCTGCAGGTGCTGGAGACATATGGACTGACAGAGGGCAACGTGGCCACCATCAACTAC 1510 CC CTGCAG T CTGGAGAC TATGG TGACAGAGGGCAACGT GC AC TCAA TAC
1	5 CCTCTGCAGATACTGGAGACGTATGGCATGACAGAGGGCAACGTAGCTACGTTCAATTAC 1104
-	1 ACAGGACAGCGGGGCGCTGTGGGGCGTGCTTCCTGGCTTTACAAGCATATCTTCCCCTTC 1570 ACAGGAC GC GGG GC GTGGGGCG GCTTCCTGGCTTTACAAGCA ATCTTCCCCTTC
	5 ACAGGACGGCAGGTGCAGTGGGGCGAGCTTCCTGGCTTTACAAGCACATCTTCCCCTTC 1164
PSEC67: 157	1 TCCTTGATTCGCTATGATGTCACCACAGGAGAGCCAATTCGGGACCCCCAGGGGCACTGT 1630 TCCTTGATTCG TA GATGTCA ACAGG GAGCC ATTCGG A CCCAGGGGCACTG
i	5 TCCTTGATTCGATACGATGTCATGACAGGGGAGCCTATTCGGAATGCCCAGGGCACTGC 1224
PSEC67: 163	1 ATGGCCACATCTCCAGGTGAGCCAGGGCTGCTGGTGGCCCCGGTAAGCCAGCAGTCCCCA 1690 ATG CCACATCTCCAGGTGAGCCAGG CT CTGGTGGCCCC GT AGCCAGCAGTCCCC
m. FATP3:122	5 ATGACCACATCTCCAGGTGAGCCAGGCCTACTGGTGGCCCCAGTGAGCCAGCAGTCCCCC 1284
PSEC67: 169	TTCCTCCCTATCCTCC C CC GACCTCGCC AGG AAG TGCT AAGGAIGIUIU
i i	TTCCTGGGCTATGCTGGGGCTCCGGAGCTGGCCAAGGACAAGCTGCTGAAGGATGTCTTC 1344
PSEC67: 175	GG CTGGGGA GTTTTCTTCAACACTGGGGACCTGCTGGTCTGCGATGACCAAGGTTTT 1810 GG CTGGGGA GTTTTCTTCAA ACTGGGGACCT TGGTCTG GATGA CAAGG TTT
1	15 TGGTCTGGGGACGTTTTCTTCAATACTGGGGACCTCTTGGTCTGTGATGAGCAAGGC111 1404
	11 CTCCGCTTCCATGATCGTACTGGAGACACCTTCAGGTGGAAGGGGGAGAATGTGGCCACA 1870 CT C CTTCCA GATCGTACTGGAGACACC TCAGGTGGAAGGG GAGAATGTGGCCACA
m. FATP3:140	D5 CTTCACTTCCACGATCGTACTGGAGACACCATCAGGTGGAAGGGAGAGAATGTGGCCACA 1464
1	71 ACCGAGGTGGCAGAGGTCTTCGAGGCCCTAGATTTTCTTCAGGAGGTGAACGTCTATGGA 1930 AC GA GTGGC GAGGTCTT GAG CCCT GA TT CTTCAGGAGGTGAAC TCTATGGA
m. FATP3:140	AC GA GIGGE GAGGIETT GAG COOT GITT TOTTCAGGAGGTGAACATCTATGGA 1524
PSEC67: 19	31 GTCACTGTGCCAGGGCATGAAGGCAGGGCTGGAATGGCAGCCCTAGTTCTGCGTCCCCC 1990 GTCAC GTGCCAGGGCA GAAGGCAGGGC GG ATGGC GCC T G TCTGCG CCCCC
m. FATP3:15	25 GTCACGGTGCCAGGGCACGAAGGCAGGGCAGGCATGGCGGCCTTGGCTCTGCGGCCCCCG 1584
PSEC67: 19	91 CACGCTTTGGACCTTATGCAGCTCTACACCCACGTGTCTGAGAACTTGCCACCTTATGCC 2050 CA GCT TG ACCT TGCAGCTCTACA CCA GT TCTGAGAACTTGCCACC TATGCC
m. FATP3:15	85 CAGGCTCTGAACCTGGTGCAGCTCTACAGCCATGTTTCTGAGAACTTGCCACCGTATGCC 1644
PSEC67: 20	51 CGGCCCCGATTCCTCAGGCTCCAGGAGTCTTTGGCCACCACAGAGACCTTCAAACAGCAG 2110 CG CC CG TT CTCAGGCTCCAGGA TCTTTGGCCAC AC GAGACCTTCAAACAGCAG
m FATP3:16	45 CGACCTCGGTTTCTCAGGCTCCAGGAATCTTTGGCCACTACTGAGACCTTCAAACAGCAG 1704

) •

図 8	
PSEC67: 2111	AAAGTTCGGATGGCAAATGAGGGCTTCGACCCCAGCACCCTGTCTGACCCACTGTACGTT 2170 AA GTT GGATGGC AATGAGGGCTT GACCCCAG CTGTCTGACCCACT TA GTT
m. FATP3:1705	AAGGTTAGGATGGCCAATGAGGGCTTTGACCCCAGTGTACTGTCTGACCCACTCTATGTT 1764
PSEC67: 2171	CTGGACCAGGCTGTAGGTGCCTACCTGCCCCTCACAACTGCCCGGTACAGCGCCCTCCTG 2230 CTGGACCA G T TAGG GCCTACCTGCCCCTCACA CTGCCCGGTACAG GCCCTCCTG
m. FATP3:1765	CTGGACCAAGATATAGGGGCCTACCTGCCCCTCACACCTGCCCGGTACAGTGCCCTCCTG 1824
PSEC67: 2231	GCAGGAAACCTTCGAATCTGA 2251 C GGA ACCTTCGAATCTGA
m FATP3:1825	TCTGGAGACCTTCGAATCTGA 1845

,	<b>,</b>	
		^

図 9	_	A CONTRACT OF THE CONTRACT OF
PSEC67:	61'	PLLLLKLHLWPQLRWLPADLAFAVRALCCKRALRARALAAAAADPEGPEGGCSLAWRLAE ******. *. *********
m. FATP3:	ı"	AAADPESSESGCSLAWRLAY
PSEC67:	121'	LAQQRAAHTFL IHGSRRFSYSEAERESNRAARAFLRALGWDWGPDGGDSGEGSAGEGERA
m. FATP3:		################################
PSEC67:	181'	ADCACDA A ACSCARE ACCIDICA ARCCICA A API SPIGATVALLLI PAGPEFLWLWFGLAKAGLR
rsecor.		## ### *, **, **, ******************
m. FATP3:	79"	APPAGD———AAAR—GTTAPPLAPGATVALLLPAGPDFLWIWFGLAKAGLR
PSEC67:	241'	TAFVPTALRRGPLLHCLRSCGARALVLAPEFLESLEPDLPALRAMGLHLWAAGPGTHPAG
2.000	105"	TAFVFTALRRGFLEHCERSCGARGEVER EF EN TAFVFTALRRGFLEHCERSCGASALVLATEFLESLEPDLPALRAMGLHLWATGPETNVAG
m. FATP3:	125"	
PSEC67:	301'	ISDLLAEVSAEVDGPVPGYLSSPQSITDTCLYIFTSGTTGLPKAARISHLKILQCQGFYQ **. **. * **. ******* . * * * *
m. FATP3:	185"	ISNLLSEAADQVDEPVPGYLSAPQNIMDTCLYIFTSGTTGLPKAARISHLKVLQCQGFYH
PSEC67:	361'	LCGVHQEDVIYLALPLYHMSGSLLGIVGCMGIGATVVLKSKFSAGQFWEDCQQHRVTVFQ
m. FATP3:	245"	**************************************
PSEC67:	421'	YIGELCRYLVNQPPSKAERGHKVRLAVGSGLRPDTWERFVRRFGPLQVLETYGLTEGNVA
m. FATP3:	305"	**************************************
PSEC67:	481'	TINYTGQRGAVGRASWLYKHIFPFSLIRYDVTTGEPIRDPQGHCMATSPGEPGLLVAPVS  *. **** **************************
m. FATP3:	365"	TFNYTGRQGAVGRASWLYKHIFPFSLIRYDVMIGEPIRNAQGHCMIISPGEFGLLVAFVS
PSEC67:	541'	QQSPFLGYAGGPELAQGKLLKDVFRPGDVFFNTGDLLVCDDQGFLRFHDRTGDTFRWKGE ************************************
m. FATP3:	425"	QQSPFLGYAGAPELAKDKLLKDVFWSGDVFFNTGDLLVCDEQGFLHFHDRTGDTIRWKGE
PSEC67:	601	NVATTEVAEVFEALDFLQEVNVYGVTVPGHEGRAGMAALVLRPPHALDLMQLYTHVSENL
m. FATP3:	485"	*********** * * ******* * *********** *
PSEC67:		DRYADDDELDLOGSLATTETEKOOKVRMANECEDPSTLSDPLYVLDQAVGAYLPLTTARY
		**************************************
m. FATP3:	545	ALI WAKAKATKIT GETEV MANAMERI, DI 21 FRANTE 11 199 49 1911 77 771 771 771 771 771 771 771 77
PSEC67:	721	' SALLAGNLRI
		<b>****</b> . *. <b>***</b>
m. FATP3:	605	" SALLSGDLRI

			a
			^



図10		
PSEC67:	61'	PLLLLKLHLWPQLRWLPADLAFAVRALCCKRALRARALAAAAADPEGPEGGCSLAWRLAE
acyl CoA:	1"	MLSAIYTVLA
PSEC67:	121'	LAQQRAAHTFL IHGSRRFSYSEAERESNRAARAFLRALGWDWGPDGGDSGEGSAGEGERA
acyl CoA:	11"	GLLFLPLLVNLCCPYFFQDIGYFLKVAAVGRRVRSYGQRRPARTILRAFLEKARQTPHKP
PSEC67:	181'	APGAGDAAAGSGAEFAGGDGAARGGGAAAPLSPGATVALLLPAGPEFLWLWFGLAKAGLR**. *****. ******. ****************
acyl CoA:	71"	FLLFRDETLTYAQVDRRSNQVARALHDHLGLRQGDCVALLMGNEPAYVWLWLGLVKLGCA
PSEC67:	241'	TAFVPTALRRGPLLHCLRSCGARALVLAPEFLESLEPDLPALRAMGLHLWAAGPGTHPAG  * * . ****
acyl CoA:	131"	MACLNYNIRAKSLLHCFQCCGAKVLLVSPELQAAVEEILPSLKKDDVSIYYVSRTSNTDG
PSEC67:	301'	ISDLLAEVSAEVDGPVPGYLSSPQSITDTCLYIFTSGTTGLPKAARISHLKILQCQGFYQ **********
acyl CoA:	191"	IDSFLDKVDEVSTEP I PESWRSEVTFSTPAL YIYTSGTTGLPKAAMITHQRIWYGTGLTF
PSEC67:	361'	LCGVHQEDVIYLALPLYHMSGSLLGIVGCMGIGATVVLKSKFSAGQFWEDCQQHRVTVFQ**
acyl CoA:	251"	VSGLKADDVIYITLPFYHSAALLIGIHGCIVAGATLALRTKFSASQFWDDCRKYNVTVIQ
PSEC67:	421'	YIGELCRYLVNQPPSKAERGHKVRLAVGSGLRPDTWERFVRRFGPLQVLETYGLTEGNVA
acyl CoA:	311"	YIGELLRYLCNSPQKPNDRDHKVRLALGNGLRGDVWRQFVKRFGDICIYEFYAATEGNIG
PSEC67:	481'	TINYTGQRGAVGRASWLYKHIFPFSLIRYDVTTGEPIRDPQGHCMATSPGEPGLLVAPVS .**.
acyl CoA:	371"	
PSEC67:	541'	QQSPFLGYAGGPELAQGKLLKDVFRPGDVFFNTGDLLVCDDQGFLR <i>FHDRTGDTFRWKGE</i> * .** ****. * * * * * * * * * * * * * *
acyl CoA:	431"	QLTPFNGYAGAKAQTEKKKLRDVFKKGDLYFNSGDLLMVDHENFIY <i>FHDRVGDTFRWKGE</i>
PSEC67:	601'	NVATTEVAEVFEALDFLQEVNVYGVTVPGHEGRAGMAALVLRPPHALDLMQLYTHVSENL
acyl CoA:	491"	NVATTEVADTVGLVDFVQEVNVYGVHVPDHEGRIGMAS I KMKENHEFDGKKLFQHIADYL
PSEC67:	661'	PPYARPRFLRLQESLATTETFKQQKVRMANEGFDPSTLSDPLYVLDQAVGAYLPLTTARY *. ******** * * . * . * . * . *
acyl CoA:	551"	PSYARPRFLRIQDTIEITGTFKHRKMTLVEEGFNPAVIKDALYFLDDTAKMYVPMTEDIY
PSEC67:	721	SALLAGNLRI
acyl CoA:	611	. *. * . * NAISAKTLKL



1

#### SEQUENCE LISTING

<110> Helix Research Institute <120> Fatty Acid Transfer Protein, and a gene encoding the protein. <130> H1-106DP3PCT <140> <141> <150> JP 1999-194179 <151> 1999-07-08 <150> JP 2000-128993 <151> 2000-04-25 <150> US 60/159586 <151> 1999-10-18 <160> 12 <170> Patentin Ver. 2.0 <210> 1 (211) 2405 <212> DNA <213> Homo sapiens <220> <221> CDS **<222> (59).. (2248) <400>** 1 gcactcctcc cgggtttctg ctctccgccc gtgtggagtg gtgggggcct gggtggga 58 106 atg ggc gtg tgc cag cgc acg cgc gct ccc tgg aag gag aag tct cag Met Gly Val Cys Gln Arg Thr Arg Ala Pro Trp Lys Glu Lys Ser Gln 1 5 10 15 cta gaa cga gcg gcc cta ggt ttt cgg aag gga gga tca ggg atg ttt 154 Leu Glu Arg Ala Ala Leu Gly Phe Arg Lys Gly Gly Ser Gly Met Phe 20 25 gcg agc ggc tgg aac cag acg gtg ccg ata gag gaa gcg ggc tcc atg Ala Ser Gly Trp Asn Gln Thr Val Pro lle Glu Glu Ala Gly Ser Met 202 35 40 45

		•
		o) A

Ala Ala Leu Leu Leu Pro Leu Leu Leu Leu Leu Pro Leu Leu Leu ctg aag cta cac ctc tgg ccg cag ttg cgc tgg ctt ccg gcg gac ttg Leu Lys Leu His Leu Trp Pro Gln Leu Arg Trp Leu Pro Ala Asp Leu gcc ttt gcg gtg cga gct ctg tgc tgc aaa agg gct ctt cga gct cgc Ala Phe Ala Val Arg Ala Leu Cys Cys Lys Arg Ala Leu Arg Ala Arg gcc ctg gcc gcg gct gcc gcc gac ccg gaa ggt ccc gag ggg ggc tgc Ala Leu Ala Ala Ala Ala Asp Pro Glu Gly Pro Glu Gly Gly Cys age etg gee tgg ege etc geg gaa etg gee cag ege gee geg cae Ser Leu Ala Trp Arg Leu Ala Glu Leu Ala Gln Gln Arg Ala Ala His acc ttt ctc att cac ggc tcg cgg cgc ttt agc tac tca gag gcg gag Thr Phe Leu lle His Gly Ser Arg Arg Phe Ser Tyr Ser Glu Ala Glu cgc gag agt aac agg gct gca cgc gcc ttc cta cgt gcg cta ggc tgg Arg Glu Ser Asn Arg Ala Ala Arg Ala Phe Leu Arg Ala Leu Gly Trp gac tgg gga ccc gac ggc ggc gac agc ggc gag ggg agc gct gga gaa Asp Trp Gly Pro Asp Gly Gly Asp Ser Gly Glu Gly Ser Ala Gly Glu ggc gag cgg gca gcg ccg gga gcc gga gat gca gcg gcc gga agc ggc Gly Glu Arg Ala Ala Pro Gly Ala Gly Asp Ala Ala Gly Ser Gly gcg gag ttt gcc gga ggg gac ggt gcc gcc aga ggt gga gga gcc gcc Ala Glu Phe Ala Gly Gly Asp Gly Ala Ala Arg Gly Gly Ala Ala gcc cct ctg tca cct gga gca act gtg gcg ctg ctc ctc ccc gct ggc Ala Pro Leu Ser Pro Gly Ala Thr Val Ala Leu Leu Leu Pro Ala Gly cca gag ttt ctg tgg ctc tgg ttc ggg ctg gcc aag gcc ggc ctg cgc Pro Glu Phe Leu Trp Leu Trp Phe Gly Leu Ala Lys Ala Gly Leu Arg 

**)** 

				gcc Ala							826
				cgc Arg							874
	_	 _	_	ctg Leu	_	_	_	_	_		922
				gga Gly 295							970
				gaa Glu							1018
				aca Thr							1066
				aag Lys							1114
				tat Tyr							1162
				cca Pro 375							1210
				ggc Gly							1258
				ttc Phe							1306
				ggg Gly							1354

ccc ( Pro I	ccg Pro	agc Ser 435	aag Lys	gca Ala	gaa Glu	cgt Arg	ggc Gly 440	cat His	aag Lys	gtc Val	cgg Arg	ctg Leu 445	gca Ala	gtg Val	ggc Gly	1402
agc ( Ser (	ggg Gly 450	ctg Leu	cgc Arg	cca Pro	gat Asp	acc Thr 455	tgg Trp	gag Glu	cgt Arg	ttt Phe	gtg Val 460	cgg Arg	cgc Arg	ttc Phe	ggg Gly	1450
CCC Pro 1 465	ctg Leu	cag Gln	gtg Vai	ctg Leu	gag Giu 470	aca Thr	tat Tyr	gga Gly	ctg Leu	aca Thr 475	gag Glu	ggc Gly	aac Asn	gtg Val	gcc Ala 480	1498
acc : Thr	atc	aac Asn	tac Tyr	aca Thr 485	gga Gly	cag Gin	cgg Arg	ggc Gly	gct Ala 490	gtg Val	ggg Gly	cgt Arg	gct Ala	tcc Ser 495	tgg Trp	1546
ctt Leu	tac Tyr	aag Lys	cat His 500	atclie	ttc Phe	ccc Pro	ttc Phe	tcc Ser <b>50</b> 5	ttg Leu	att He	cgc Arg	tat Tyr	gat Asp 510	gtc Val	acc Thr	1594
aca ; Thr	gga Gly	gag Glu 515	cca Pro	att	cgg Arg	gac Asp	ccc Pro <b>520</b>	cag Gln	ggg Gly	cac His	tgt Cys	atg Met 525	gcc Ala	aca Thr	tct Ser	1642
cca : Pro	ggt Gly 530	gag Glu	cca Pro	ggg Gly	ctg Leu	ctg Leu 535	gtg Val	gcc Ala	ccg Pro	gta Vai	agc Ser <b>540</b>	cag Gln	cag Gln	tcc Ser	cca Pro	1690
ttc Phe 545	ctg Leu	ggc Gly	tat Tyr	gct Ala	ggc Gly 550	ggg Gly	cca Pro	gag Glu	ctg Leu	gcc Ala 555	cag GIn	ggg Gly	aag Lys	ttg Leu	cta Leu 560	1738
aag Lys	gat Asp	gtc Val	ttc Phe	cgg Arg 565	cct Pro	ggg Gly	gat Asp	gtt Val	ttc Phe 570	ttc Phe	aac Asn	act Thr	ggg Gly	gac Asp 575	c t g Leu	1786
ctg Leu	gtc Vai	tgc Cys	gat Asp 580	gac Asp	caa Gin	ggt Gly	ttt Phe	ctc Leu <b>58</b> 5	cgc Arg	ttc Phe	cat His	gat Asp	cgt Arg 590	act Thr	gga Gly	1834
gac Asp	acc Thr	ttc Phe 595	agg Arg	tgg Trp	aag Lys	ggg Gly	gag Glu 600	aat Asn	gtg Val	gcc Ala	aca Thr	acc Thr 605	gag Glu	gtg Val	gca Ala	1882
gag Glu	gtc Val 610	ttc Phe	gag Glu	gcc Ala	cta Leu	gat Asp 615	ttt Phe	ctt Leu	cag Gin	gag Glu	gtg Val 620	Asn	gtc Val	tat Tyr	gga Gly	1930

•		
	· ·	
		,
•		•
		•-
		ì
		,

										gga Gly 635						1978
										cag Gin						2026
										cga Arg						2074
gag Glu	tct Ser	ttg Leu 675	gcc Ala	acc Thr	aca Thr	gag Glu	acc Thr 680	ttc Phe	aaa Lys	cag Gln	cag Gln	aaa Lys 685	gtt Val	cgg Arg	atg Met	2122
										tct Ser						2170
										ctc Leu 715						2218
							ctt Leu			tgag	gaac	ttc	caca	cctga	ag	2268
gca	cctga	aga g	gagga	acto	et gi	gggg	gtggg	g gg	ccgt	tgca	ggt	gtac	tgg i	gctg	tcaggg	2328
atci	tttt	cta 1	tacca	agaa	ct go	ggto	cacta	ı tt	ttgta	aata	aat	gtgg	ctg	gagc	tgatcc	2388
agc	tgtc	tct	gacci	tac												2405

<210> 2

<211> 730

<212> PRT

<213> Homo sapiens


<400> 2

Met Gly Val Cys Gln Arg Thr Arg Ala Pro Trp Lys Glu Lys Ser Gln
1 5 10 15


Leu Glu Arg Ala Ala Leu Gly Phe Arg Lys Gly Gly Ser Gly Met Phe 20 25 30

			٠
			•
			•
			y

Ala Ser Gly Trp Asn Gln Thr Val Pro lle Glu Glu Ala Gly Ser Met 35 40 Ala Ala Leu Leu Leu Pro Leu Leu Leu Leu Pro Leu Leu Leu Leu Lys Leu His Leu Trp Pro Gln Leu Arg Trp Leu Pro Ala Asp Leu 75 Ala Phe Ala Val Arg Ala Leu Cys Cys Lys Arg Ala Leu Arg Ala Arg 95 85 Ala Leu Ala Ala Ala Ala Asp Pro Glu Gly Pro Glu Gly Gly Cys 100 105 Ser Leu Ala Trp Arg Leu Ala Glu Leu Ala Gln Gln Arg Ala Ala His 115 120 Thr Phe Leu lle His Gly Ser Arg Arg Phe Ser Tyr Ser Glu Ala Glu Arg Glu Ser Asn Arg Ala Ala Arg Ala Phe Leu Arg Ala Leu Gly Trp 160 155 145 150 Asp Trp Gly Pro Asp Gly Gly Asp Ser Gly Glu Gly Ser Ala Gly Glu 165 170 Gly Glu Arg Ala Ala Pro Gly Ala Gly Asp Ala Ala Gly Ser Gly 185 180 Ala Glu Phe Ala Gly Gly Asp Gly Ala Ala Arg Gly Gly Gly Ala Ala Ala Pro Leu Ser Pro Gly Ala Thr Val Ala Leu Leu Leu Pro Ala Gly 215 220 210 Pro Glu Phe Leu Trp Leu Trp Phe Gly Leu Ala Lys Ala Gly Leu Arg 225 Thr Ala Phe Val Pro Thr Ala Leu Arg Arg Gly Pro Leu Leu His Cys Leu Arg Ser Cys Gly Ala Arg Ala Leu Val Leu Ala Pro Glu Phe Leu 265 270 Glu Ser Leu Glu Pro Asp Leu Pro Ala Leu Arg Ala Met Gly Leu His 285 275 280



Leu Trp Ala Aia Gly Pro Gly Thr His Pro Ala Gly lle Ser Asp Leu Leu Ala Giu Vai Ser Ala Giu Vai Asp Giy Pro Vai Pro Giy Tyr Leu Ser Ser Pro Gin Ser lie Thr Asp Thr Cys Leu Tyr lie Phe Thr Ser Gly Thr Thr Gly Leu Pro Lys Ala Ala Arg lle Ser His Leu Lys lle Leu Gln Cys Gln Gly Phe Tyr Gln Leu Cys Gly Val His Gln Glu Asp Val lie Tyr Leu Ala Leu Pro Leu Tyr His Met Ser Gly Ser Leu Leu Gly lie Val Gly Cys Met Gly lie Gly Ala Thr Val Val Leu Lys Ser Lys Phe Ser Ala Gly Gln Phe Trp Glu Asp Cys Gln Gln His Arg Val Thr Val Phe Gin Tyr lle Gly Glu Leu Cys Arg Tyr Leu Val Asn Gin Pro Pro Ser Lys Ala Glu Arg Gly His Lys Val Arg Leu Ala Val Gly Ser Gly Leu Arg Pro Asp Thr Trp Glu Arg Phe Val Arg Arg Phe Gly Pro Leu Gin Val Leu Glu Thr Tyr Gly Leu Thr Glu Gly Asn Val Ala Thr lie Asn Tyr Thr Gly Gln Arg Gly Ala Val Gly Arg Ala Ser Trp Leu Tyr Lys His Ile Phe Pro Phe Ser Leu Ile Arg Tyr Asp Val Thr Thr Gly Glu Pro lle Arg Asp Pro Gln Gly His Cys Met Ala Thr Ser Pro Gly Glu Pro Gly Leu Leu Val Ala Pro Val Ser Gin Gln Ser Pro 



Phe Leu Gly Tyr Ala Gly Gly Pro Glu Leu Ala Gln Gly Lys Leu Leu 545 550 555 560 Lys Asp Val Phe Arg Pro Gly Asp Val Phe Phe Asn Thr Gly Asp Leu 565 570 Leu Val Cys Asp Asp Gln Gly Phe Leu Arg Phe His Asp Arg Thr Gly 580 585 Asp Thr Phe Arg Trp Lys Gly Glu Asn Val Ala Thr Thr Glu Val Ala 600 Glu Val Phe Glu Ala Leu Asp Phe Leu Gin Glu Val Asn Val Tyr Gly 610 615 620 Val Thr Val Pro Gly His Glu Gly Arg Ala Gly Met Ala Ala Leu Val 625 630 Leu Arg Pro Pro His Ala Leu Asp Leu Met Gln Leu Tyr Thr His Val 650 Ser Glu Asn Leu Pro Pro Tyr Ala Arg Pro Arg Phe Leu Arg Leu Gln 665 Glu Ser Leu Ala Thr Thr Glu Thr Phe Lys Gin Gin Lys Val Arg Met 675 680 685 Ala Asn Giu Gly Phe Asp Pro Ser Thr Leu Ser Asp Pro Leu Tyr Val 690 695 Leu Asp Gin Ala Val Gly Ala Tyr Leu Pro Leu Thr Thr Ala Arg Tyr 715 720 Ser Ala Leu Leu Ala Gly Asn Leu Arg lle 725 730

<210> 3

<211> 30

<212> RNA

<213> Artificial Sequence

<220>


(223) Description of Artificial Sequence: Artificially Synthesized Oligo-cap Linker

<400> 3 agcaucgagu cggccuuguu ggccuacugg

<210> 4 <211> 42 <212> DNA <213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artificially</pre>	
<400> 4 gcggctgaag acggcctatg tggcctttt tttttttt tt	42
<210> 5 <211> 21 <212> DNA <213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artificially</pre>	
<400> 5 agcatcgagt cggccttgtt g	21
<210> 6 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: Artificially Synthesized Primer Sequence	
<400> 6 gcggctgaag acggcctatg t	21
<210> 7 <211> 36 <212> DNA <213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artificially</pre>	

# Synthesized Primer Sequence

<400> 7 ggaattccgt ggagtggtgg gggcctgggt gggaat	36
<210> 8 <211> 39 <212> DNA <213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artificially</pre>	
<400> 8 cgggatccca cctgcaacgg cccccacccc acagagttc	39
<210> 9 <211> 36 <212> DNA <213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artificially</pre>	
<400> 9 ggaattccgt ggagtggtgg gggcctgggt gggaat	36
<210> 10 <211> 29 <212> DNA <213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artificially</pre>	
<400> 10 cgggatccga ttcgaaggtt tcctgccag	29
<210> 11 <211> 20 <212> DNA	



<213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artis</pre>	ficially
<b>&lt;400&gt; 11</b>	
aacagggctg cacgcgcctt	20
<210> 12 <211> 39 <212> DNA <213> Artificial Sequence	
<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:Artificial Synthesized Primer Sequence</pre>	ficially
<400> 12 cgggatccca cctgcaacgg cccccacccc acagagttc	39

·	·		
		·	•
			Rg.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/04549

A. CLASS Int.	SIFICATION OF SUBJECT MATTER C1 <sup>7</sup> C12N15/12, 5/10, 1/15, 1/1 C07K14/47, 16/18, C12Q1/02 C12P21/02,		
According to	o International Patent Classification (IPC) or to both na	ational classification and IPC	
	S SEARCHED		
	ocumentation searched (classification system followed C1 <sup>7</sup> C12N15/00-15/90	by classification symbols)	
	ion searched other than minimum documentation to the		
GENE SWIS	ata base consulted during the international search (name BANK/DDBJ/EMBL/GENESEQ SSPROT/PIR/GENESEQ SIS/MEDLINE/WPI (STN)	e of data base and, where practicable, sea	rch terms used)
C. DOCUI	MENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.
P,X	WO, 99-46281, A2 (GENENTECH INC 16 September, 1999 (16.09.99), Full text (Family: none)	C.),	1-16
P,X	WO, 99-36537, A2 (MILLENNIUM PR 22 July, 1999 (22.07.99), Full text & AU, 9923108, A	HARM INC.),	1-16
х	Biochimica et Biophysica Acta, Barbara A. Fitscher et al., "Tiss cloning of a human fatty acid trans p.381-385	sue distribution and cDNA	1-16
х	Proc. Natl. Acad. Sci. USA, 95, David Hirsch et al., "A family of conserved from mycobacterium to	fatty acid transporters	1-16
A	Cell, 79, Nov.1994 Jean E. Schaffer et al., "Expre characterization of a novel adi	ession cloning and pocyte long chain fatty	1-16
Further	r documents are listed in the continuation of Box C.	See patent family annex.	
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier document but published on or after the international filing date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family		ne application but cited to erlying the invention cannot be red to involve an inventive claimed invention cannot be claimed invention cannot be p when the document is documents, such a skilled in the art family	
03 0	actual completion of the international search october, 2000 (03.10.00)	Date of mailing of the international sear 24 October, 2000 (24	1.10.00)
	ailing address of the ISA/ nese Patent Office	Authorized officer	
Facsimile No	<b>D.</b>	Telephone No.	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/04549

(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	acid transport protein",p.427-436	
A	J. Biol. Chem., 271(48), Nov.1996 A. Uchiyama et al., "Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase", p.30360-30365	1-16
A	Circulation, 96(8)suppl., 1997 Jean E. Schaffer et al., "Cloning and structure-function analysis of human heart fatty acid transport protein", p. I363	1-16
=		

#### 国際調査報告

A. 発明の属する分野の分類(国際特許分類(IPC))

Int. C1 C12N15/12, 5/10, 1/15, 1/19, 1/21, C12P21/02 C07K14/47, 16/18, C12Q1/02, 1/68

#### B. 調査を行った分野

調査を行った最小限資料(国際特許分類(IPC))

Int. Cl' C12N15/00-15/90

最小限資料以外の資料で調査を行った分野に含まれるもの

国際調査で使用した電子データベース(データベースの名称、調査に使用した用語)

GENBANK/DDBJ/EMBL/GENESEQ

SWISSPROT/PIR/GENESEQ

BIOSIS/MEDLINE/WPI (STN)

## C. 関連すると認められる文献

P, X WO, 99-46281, A2 (GENENTECH INC.) 16. 9月. 1999 (16. 09. 99) 全文 (ファミリーなし)	引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
	P, X	(GENENTECH INC.) 16.9月.1999 (16.09.99) 全文	1-16

## X C欄の続きにも文献が列挙されている。

□ パテントファミリーに関する別紙を参照。

- \* 引用文献のカテゴリー
- 「A」特に関連のある文献ではなく、一般的技術水準を示す もの
- 「E」国際出願日前の出願または特許であるが、国際出願日 以後に公表されたもの
- 「L」優先権主張に疑義を提起する文献又は他の文献の発行 日若しくは他の特別な理由を確立するために引用する 文献(理由を付す)
- 「O」ロ頭による開示、使用、展示等に言及する文献
- 「P」国際出願日前で、かつ優先権の主張の基礎となる出願

- の日の後に公表された文献
- 「T」国際出願日又は優先日後に公表された文献であって 出願と矛盾するものではなく、発明の原理又は理論 の理解のために引用するもの
- 「X」特に関連のある文献であって、当該文献のみで発明 の新規性又は進歩性がないと考えられるもの
- 「Y」特に関連のある文献であって、当該文献と他の1以 上の文献との、当業者にとって自明である組合せに よって進歩性がないと考えられるもの
- 「&」同一パテントファミリー文献

国際調査を完了した日 03.10.00 国際調査報告の発送日 24.10.00 国際調査機関の名称及びあて先 日本国特許庁(ISA/JP) 野便番号100-8915 東京都千代田区霞が関三丁目4番3号 電話番号 03-3581-1101 内線 3448

## 国際調査報告

C (続き).	関連すると認められる文献	
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号
P, X	WO, 99-36537, A2 (MILLENNIUM PHARM INC.) 22.7月.1999 (22.07.99)	1 - 1 6
X	全文 & AU, 9923108, A Biochimica et Biophysica Acta, 1443, 1998 Barbara A. Fitscher et al., "Tissue distribution and cDNA cloning of a human fatty acid transport protein(hsFATP4)", p. 381-385	1-16
X	Proc. Natl. Acad. Sci. USA, 95, July 1998 David Hirsch et al., "A family of fatty acid transporters conserved from mycobacterium to man", p. 8625-8629	1-16
А	Cell, 79, Nov. 1994  Jean E. Schaffer et al., "Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein", p. 427-436	1-16
A	J. Biol. Chem., 271 (48), Nov. 1996 A. Uchiyama et al., "Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase", p. 30360-30365	1-16
A	Circulation, 96(8) suppl., 1997 Jean E. Schaffer et al., "Cloning and structure-function analysis of human heart fatty acid transport protein", p. I363	1-16